| Name | Title | Contact Details |
|---|
Prejuvenation Aesthetics is a med spa in Ashburn, VA that specializes in preventative cosmetic treatments to enhance natural facial features and boost confidence.
Southwestern Health Resources, which blends the strengths of University of Texas Southwestern Medical Center and Texas Health Resources, includes a network of 29 hospital locations and more than 5,000 physicians, committed to being the national leader in population health. With more than 500 points of access to care, this provides for higher value and allows patients to access services across a full continuum of medical needs. The network serves people across 17 counties in North Texas. In total, Southwestern Health coordinates care for more than 650,000 patients, aligned with commercial health care plans and Medicare programs. SWHR operates the nation`s highest rated Next Generation Accountable Care Organization for savings.
Frontline Dental Implant Specialists (FDIS) is a dental implant partnership network that brings together top dental implant specialists with over 150+ years of combined experience.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
SCRI, an industry leader in clinical trials, is dedicated to advancing therapies for patients through clinical research.